semaglutide la crosse wi π€© ππππ ππ‘ π¦π§π’ππ π€© π³πΊππππ»π πΎ ππΎππππ-π πππ, πΏππ π»πΎπΏπππΎ πΊππ½ πΊπΏππΎπ πππππππ πΊπ ππππ πππ ππ½πΊπ π½ππππΎπ ππΊπ»π πΎπ! π’πΊπ π ππ πππ½πΊπ ππ π»πππ ππ ππΏ πππ ππΊππΎ πΊππ University of Wisconsin, La Crosse
Description
The once-a-day pill, from the makers of the Wegovy weight-loss jab, can now be bought privately in UK pharmacies.

The results challenge the viral GLP-1 muscle wasting narrative
GLP-1 receptor agonists like semaglutide are powerful weight loss tools, but they are not suitable for everyone

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.“Psoriatic arthritis seems to have a special place for increased risk for obesity,&rdquo

Explore how GLP-1 therapies may reduce gout risk by lowering uric acid in patients with obesity and type 2 diabetes.
